We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

28 hedge funds and large institutions have $7.9M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

4% more funds holding

Funds holding: 27 → 28 (+1)

9% less capital invested

Capital invested by funds: $8.67M → $7.9M (-$773K)

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$491K
2
ECM
ExodusPoint Capital Management
New York
+$43.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$21.9K
4
Marshall Wace
Marshall Wace
United Kingdom
+$17.2K
5
Jane Street
Jane Street
New York
+$14.3K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$193K
2
Citadel Advisors
Citadel Advisors
Florida
-$144K
3
Renaissance Technologies
Renaissance Technologies
New York
-$44K
4
Millennium Management
Millennium Management
New York
-$9.27K
5
LPL Financial
LPL Financial
California
-$8.32K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.94M +$491K +35,800 +36%
PM
2
Prosight Management
Texas
$1.58M -$193K -14,096 -11%
SRC
3
Sage Rhino Capital
California
$1.22M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$638K – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$483K – – –
Goldman Sachs
6
Goldman Sachs
New York
$452K – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$449K – – –
ECM
8
ExodusPoint Capital Management
New York
$388K +$43.9K +3,203 +13%
Marshall Wace
9
Marshall Wace
United Kingdom
$255K +$17.2K +1,251 +8%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$180K +$13.7K +1,001 +9%
RCMNY
11
Rubric Capital Management (New York)
New York
$83.7K – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$47.3K -$44K -3,206 -49%
State Street
13
State Street
Massachusetts
$40.8K – – –
BlackRock
14
BlackRock
New York
$33.7K – – –
Northern Trust
15
Northern Trust
Illinois
$24.6K – – –
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$22.9K +$21.9K +1,599 New
Jane Street
17
Jane Street
New York
$15K +$14.3K +1,045 New
XT
18
XTX Topco
Cayman Islands
$13.1K +$96 +7 +0.8%
Two Sigma Investments
19
Two Sigma Investments
New York
$10.2K -$1.92K -140 -16%
HF
20
HRT Financial
New York
$10K +$10.1K +735 New
HCM
21
Hollencrest Capital Management
California
$7.16K – – –
TRCT
22
Tower Research Capital (TRC)
New York
$5K -$631 -46 -12%
Morgan Stanley
23
Morgan Stanley
New York
$1.25K – – –
BTC
24
Bank & Trust Company
Illinois
$716 – – –
UBS Group
25
UBS Group
Switzerland
$171 +$165 +12 New
1
2

VINC Hedge Fund Activity: Q3 2024 in Review

28 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2024, worth a combined $7.9M — down 8.9% from $8.67M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VINC positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, adding an estimated $491K. The largest seller was Prosight Management, cutting an estimated $193K.

  • 28 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2024, up from 27 in Q2 2024.
  • Funds reported $7.9M of Vincerx Pharma, Inc. Common Stock stock for Q3 2024, down 8.9% quarter-over-quarter.
  • 6 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2024 and 5 closed out, a net change of +1 holder.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2024 was Armistice Capital, an estimated $491K added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2024 was Prosight Management, an estimated $193K sold.

Based on aggregated 13F filings for Q3 2024.